Vera Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results
Key Highlights
- ➤TRUTAKNA generated $10.3 million Q3 net product revenue after U.S. launch.
- ➤Approximately 700 Patient Start Forms received since TRUTAKNA’s July accelerated approval.
- ➤ORIGIN 3 showed a 76% lower composite kidney progression risk versus placebo through two years.
- ➤Vera submitted an FDA sBLA for full TRUTAKNA approval, expected in mid-2027.
- ➤Q3 net loss widened to $93.7 million from $80.3 million year over year.
Expert Statements
Marshall Fordyce, M.D., Founder and Chief Executive Officer of Vera Therapeutics
“We are excited by the early momentum of the TRUTAKNA launch, which exemplifies our long-standing confidence in its potential to become a foundational therapy in IgAN. Our transition to a commercial-stage company marks a new chapter for Vera, as we deliver on our commitment to people living with IgAN.”
Marshall Fordyce, M.D., Founder and Chief Executive Officer of Vera Therapeutics
“We recently presented the final efficacy results from the ORIGIN 3 trial at ASN Kidney Week 2026, strengthening the clinical foundation for TRUTAKNA. The stabilization of kidney function at the physiologic rate and significant reduction in risk of composite kidney disease progression through two years reinforce the potential for TRUTAKNA to change the course of IgAN and supported our recent submission of an sBLA for full FDA approval.”
Matt Skelton, Chief Commercial Officer of Vera Therapeutics
“Our team is executing on the launch priorities we established for TRUTAKNA, with growing interest from the IgAN community and approximately 700 PSFs received since launch. We are encouraged by the payer coverage policies taking shape. Our focus remains on expanding access and ensuring nephrologists have the tools and education they need to help eligible patients begin treatment with TRUTAKNA.”
* TRUTAKNA(®) (atacicept-vymj) U.S. launch building early momentum following July 7 accelerated approval by the U.S. Food and Drug Administration (FDA) with approximately 700 Patient Start Forms (PSFs) to date and $10.3 million of net product revenue in Q3. * ORIGIN 3 final efficacy analysis demonstrated stabilization of kidney function and a 76% reduction in risk of composite kidney disease progression versus placebo through two years; data was presented as a late-breaking oral presentation at the opening plenary session at ASN Kidney Week 2026 with a simultaneous publication in The New England Journal of Medicine. * Completed supplemental Biologics License Application (sBLA) submission to the FDA for full approval of TRUTAKNA in adults with primary IgAN. * Management to host a live investor webcast at 4:30 p.m. ET on November 5, 2026. BRISBANE, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a commercial-stage biotechnology company, today reported its business highlights and financial results for the quarter ended September 30, 2026.
Get started
Create a free account to read the full story.